EUVIMEDEUVIMED entdecken
Multizentrische Studie

Differential Prognosis and Transplant Strategies in CBF ‐ AML With RUNX1 :: RUNX1T1 Versus CBFβ :: MYH11 Fusions

Jingtao Huang iD, Huihong Huang iD, Yunxiang Zhang iD, Yi Xia iD, Yuqing Tu iD, Hao Xu iD, Yeqian Zhao iD, Jiayu Huang iD, Han Yan iD, Zengkai Pan iD, Chuanhe Jiang iD, Luxiang Wang iD und 8 weitere

American Journal of Hematology · 2026-05 · 101 (5) · 972-985

DOI: 10.1002/ajh.70237 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 14.02.2026. Verfasst von Jingtao Huang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, RUNX1 Translocation Partner 1 Protein, Core Binding Factor Alpha 2 Subunit. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission Project of Disciplines of Excellence, National Research Center for Translational Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Core binding factor acute myeloid leukemia (CBF‐AML) is defined by t(8;21) or inv. (16), which give rise to the RUNX1::RUNX1T1 and CBFβ::MYH11 fusion genes, respectively. CBF‐AML is a favorable‐risk AML subtype, yet differences in mutation profiles, measurable residual disease (MRD) response, and relapse risk may warrant tailored treatment approaches. We reviewed adult AML patients treated at five transplant centers across China and identified 825 de novo CBF‐AML cases, of which 779 met our eligibility criteria: 536 harbored the RUNX1::RUNX1T1 fusion and 243 the CBFβ::MYH11 fusion. The 3‐year overall survival (OS) was 80.6% for RUNX1::RUNX1T1 and 90.2% for CBFβ::MYH11 cases ( p = 0.011). Among patients with RUNX1::RUNX1T1 , those achieving MRD negativity after two consolidation cycles (PC2) had significantly better OS than nonresponders (86.3% vs. 76.5%, p = 0.008); no difference was observed for CBFβ::MYH11 patients. For RUNX1::RUNX1T1 nonresponders, allogeneic hematopoietic cell transplantation (allo‐HCT) in first complete remission (CR1) reduced relapse (CR1‐HCT vs. non‐CR1‐HCT, 8.3% vs. 18.9%; p = 0.024) and improved OS (CR1‐HCT vs. non‐CR1‐HCT vs. chemotherapy, 85.8% vs. 71.4% vs. 64.9%; p < 0.001). In CBFβ::MYH11 patients, deferring allo‐HCT until second complete remission (CR2) was associated with comparable outcomes. In RUNX1::RUNX1T1 patients, older age, elevated initial white blood cell count, lower hemoglobin, lower initial fusion transcript load, and the presence of FLT3‐ITD or KIT D816/D822 mutations were associated with an increased likelihood of PC2 nonresponse. Based on these variables, we developed a weighted scoring system with good discrimination to identify RUNX1::RUNX1T1 patients at high risk of PC2 nonresponse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteOncogene Proteins, FusionRUNX1 Translocation Partner 1 ProteinCore Binding Factor Alpha 2 SubunitHematopoietic Stem Cell TransplantationCore Binding Factor beta SubunitMyosin Heavy ChainsHumansFemaleAdultMiddle AgedMalePrognosisAdolescentNeoplasm, ResidualAgedYoung Adult

Stichwörter der Autor:innen

allogeneic hematopoietic cell transplantationcore binding factor acute myeloid leukemiameasurable residual disease

Substanzen

Oncogene Proteins, FusionRUNX1 Translocation Partner 1 ProteinCore Binding Factor Alpha 2 SubunitCBFbeta-MYH11 fusion proteinCore Binding Factor beta SubunitRUNX1T1 protein, humanRUNX1 protein, humanCBFB protein, humanMyosin Heavy Chains

Autor:innen und Institutionen

  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, C…
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
  • National Clinical Research Center for Hematologic Diseases, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou…
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Jingtao Huang, Huihong Huang, Yunxiang Zhang, Yi Xia, Yuqing Tu, Hao Xu, Yeqian Zhao, Jiayu Huang, Han Yan, Zengkai Pan, Chuanhe Jiang, Luxiang Wang, Zilu Zhang, Xiangqin Weng, YongMei Zhu, Yanmin Zhao, Yang Cao, Jia Chen, Xiaodong Mo, Xiaoxia Hu

Förderung

  • National Natural Science Foundation of China
  • Shanghai Municipal Health Commission Project of Disciplines of Excellence
  • National Research Center for Translational Medicine

Zitieren

APA

Huang, J., Huang, H., Zhang, Y., Xia, Y., Tu, Y., Xu, H., Zhao, Y., Huang, J., Yan, H., Pan, Z., Jiang, C., Wang, L., Zhang, Z., Weng, X., Zhu, Y., Zhao, Y., Cao, Y., Chen, J., Mo, X., & Hu, X. (2026). Differential Prognosis and Transplant Strategies in CBF ‐ AML With RUNX1 :: RUNX1T1 Versus CBFβ :: MYH11 Fusions. American Journal of Hematology, 101(5), 972-985. https://doi.org/10.1002/ajh.70237

Vancouver

Huang J, Huang H, Zhang Y, Xia Y, Tu Y, Xu H, et al. Differential Prognosis and Transplant Strategies in CBF ‐ AML With RUNX1 :: RUNX1T1 Versus CBFβ :: MYH11 Fusions. American Journal of Hematology. 2026;101(5):972-985. doi:10.1002/ajh.70237

BibTeX
@article{Huang2026,
  author = {Huang, Jingtao and Huang, Huihong and Zhang, Yunxiang and Xia, Yi and Tu, Yuqing and Xu, Hao and Zhao, Yeqian and Huang, Jiayu and Yan, Han and Pan, Zengkai and Jiang, Chuanhe and Wang, Luxiang and Zhang, Zilu and Weng, Xiangqin and Zhu, YongMei and Zhao, Yanmin and Cao, Yang and Chen, Jia and Mo, Xiaodong and Hu, Xiaoxia},
  title = {Differential Prognosis and Transplant Strategies in CBF ‐ AML With RUNX1 :: RUNX1T1 Versus CBFβ :: MYH11 Fusions},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {5},
  pages = {972--985},
  doi = {10.1002/ajh.70237}
}
Kostenlos starten →